CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2070.0
(-1.66%)
KRW 2070.0
(-1.66%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 46.00 KRW | 419.41% |
| 2022 | -13.96 KRW | -160.7% |
| 2021 | 23.00 KRW | 1050.0% |
| 2020 | 2.00 KRW | 9159.26% |
| 2019 | 0.02 KRW | -99.66% |
| 2018 | 6.31 KRW | 2.27% |
| 2017 | 6.17 KRW | 701.3% |
| 2016 | 0.77 KRW | -94.9% |
| 2015 | 15.10 KRW | 6.86% |
| 2014 | 14.13 KRW | 34.96% |
| 2013 | 10.47 KRW | 19.66% |
| 2012 | 8.75 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 43.00 KRW | 166.58% |
| 2024 Q1 | 16.13 KRW | 116.84% |
| 2023 Q2 | 27.00 KRW | 42.11% |
| 2023 FY | - KRW | 419.41% |
| 2023 Q4 | -95.80 KRW | -604.21% |
| 2023 Q1 | 19.00 KRW | 110.5% |
| 2023 Q3 | 19.00 KRW | -29.63% |
| 2022 Q3 | 1.83 KRW | -80.22% |
| 2022 FY | - USD | -160.7% |
| 2022 Q4 | -180.98 KRW | -9989.62% |
| 2022 Q2 | 9.25 KRW | 65.47% |
| 2022 Q1 | 5.59 KRW | 19.44% |
| 2021 Q1 | 4.45 KRW | -33.48% |
| 2021 FY | - USD | 1050.0% |
| 2021 Q2 | 6.60 KRW | 48.31% |
| 2021 Q3 | 7.18 KRW | 8.79% |
| 2021 Q4 | 4.68 KRW | -34.82% |
| 2020 Q3 | 2.82 KRW | 872.41% |
| 2020 Q1 | 2.70 KRW | 5.88% |
| 2020 Q2 | 0.29 KRW | -89.26% |
| 2020 FY | - USD | 9159.26% |
| 2020 Q4 | 6.69 KRW | 137.23% |
| 2019 Q2 | 3.22 KRW | 2.88% |
| 2019 Q4 | 2.55 KRW | -26.51% |
| 2019 Q1 | 3.13 KRW | 174.56% |
| 2019 Q3 | 3.47 KRW | 7.76% |
| 2019 FY | - USD | -99.66% |
| 2018 FY | - USD | 2.27% |
| 2018 Q4 | 1.14 KRW | -16.18% |
| 2018 Q3 | 1.36 KRW | -19.05% |
| 2018 Q2 | 1.68 KRW | -21.13% |
| 2018 Q1 | 2.13 KRW | 37.42% |
| 2017 Q1 | 1.60 KRW | 190.91% |
| 2017 Q2 | 2.32 KRW | 45.0% |
| 2017 Q3 | 0.69 KRW | -70.26% |
| 2017 FY | - USD | 701.3% |
| 2017 Q4 | 1.55 KRW | 124.64% |
| 2016 FY | - USD | -94.9% |
| 2016 Q4 | 0.55 KRW | 103.7% |
| 2016 Q3 | 0.27 KRW | -68.97% |
| 2016 Q2 | 0.87 KRW | 198.86% |
| 2016 Q1 | -0.88 KRW | -140.55% |
| 2015 Q2 | 4.45 KRW | 14.69% |
| 2015 Q1 | 3.88 KRW | 1.04% |
| 2015 FY | - USD | 6.86% |
| 2015 Q4 | 2.17 KRW | -52.72% |
| 2015 Q3 | 4.59 KRW | 3.15% |
| 2014 Q4 | 3.84 KRW | -7.47% |
| 2014 Q3 | 4.15 KRW | 18.57% |
| 2014 Q2 | 3.50 KRW | 32.58% |
| 2014 Q1 | 2.64 KRW | 3.94% |
| 2014 FY | - USD | 34.96% |
| 2013 Q1 | 2.45 KRW | 25.64% |
| 2013 FY | - USD | 19.66% |
| 2013 Q3 | 2.66 KRW | -5.67% |
| 2013 Q2 | 2.82 KRW | 15.1% |
| 2013 Q4 | 2.54 KRW | -4.51% |
| 2012 Q4 | 1.95 KRW | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -666.05 KRW | 106.906% |
| Celltrion Pharm, Inc. | 539.00 KRW | 91.466% |
| Huons Global Co., Ltd. | 3133.85 KRW | 98.532% |
| DongKook Pharmaceutical Co., Ltd. | 1073.13 KRW | 95.713% |
| Enzychem Lifesciences Corporation | -109.81 KRW | 141.891% |
| Humedix Co., Ltd. | 2512.11 KRW | 98.169% |
| Boditech Med Inc. | 1181.00 KRW | 96.105% |
| EuBiologics Co., Ltd. | -381.00 KRW | 112.073% |
| FutureChem Co.,Ltd | -303.61 KRW | 115.151% |
| Huons Co., Ltd. | 4261.00 KRW | 98.92% |
| BNC Korea Co., Ltd. | 388.00 KRW | 88.144% |
| AptaBio Therapeutics Inc. | -540.91 KRW | 108.504% |